Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Introduced Apr 6, 2026 by Rep. Mike Quigley
Both chambers passed it. It's headed to the President to be signed or vetoed.
This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases.
The bill reauthorizes
grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials,
grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and
Read the full summary on Congress.govSummary by the Congressional Research Service.
No recorded roll-call vote on this bill — it may have passed by voice vote or unanimous consent, which don't record individual votes.
- Sep 28, 2026Passed Senate without amendment by Voice Vote. (consideration: CR S5120)
- Sep 28, 2026Passed/agreed to in Senate: Passed Senate without amendment by Voice Vote. (consideration: CR S5120)
- Jul 23, 2026Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466.
- Jul 22, 2026Motion to reconsider laid on the table Agreed to without objection.
- Jul 22, 2026On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
- Jul 22, 2026Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
- Jul 22, 2026Considered as unfinished business. (consideration: CR H5159)
- Jul 20, 2026At the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Guthrie objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn.
- Jul 20, 2026DEBATE - The House proceeded with forty minutes of debate on H.R. 8205.
- Jul 20, 2026Considered under suspension of the rules. (consideration: CR H4652-4654; text: CR H4653)
- Jul 20, 2026Mr. Guthrie moved to suspend the rules and pass the bill, as amended.
- Jul 9, 2026Placed on the Union Calendar, Calendar No. 637.
- Jul 9, 2026Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.
- May 21, 2026Ordered to be Reported (Amended) by the Yeas and Nays: 46 - 0.
- May 21, 2026Committee Consideration and Mark-up Session Held
- May 13, 2026Forwarded by Subcommittee to Full Committee by Voice Vote.
- May 13, 2026Subcommittee Consideration and Mark-up Session Held
- Apr 6, 2026Referred to the Subcommittee on Health.
- Apr 6, 2026Referred to the House Committee on Energy and Commerce.
- Apr 6, 2026Introduced in House